As previously reported, Maxim initiated coverage of Anebulo Pharmaceuticals – which is developing ANEB-001 as an acute cannabis intoxication, or ACI, reversal agent – with a Buy rating and $6 price target. While “rarely fatal,” ACI represents “a significant cause of emergency department visits,” says the analyst, who sees a significant unmet need for ACI with a growing opportunity driven by favorable industry trends. The analyst, who notes that ANEB-001 is currently in an ongoing Phase 2 study, does not believe “the opportunity is fully captured at the current market cap.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ANEB:
- Anebulo Pharmaceuticals reports Q4 EPS (10c), consensus (11c)
- Anebulo Pharmaceuticals initiated with a Buy at H.C. Wainwright
- ANEB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Anebulo Pharmaceuticals announces feedback from FDA on ANEB-001 path
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue